Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
A combination of the investigational therapy cediranib and Lynparza (olaparib) fails to delay disease progression in women with platinum-sensitive relapsed ovarian cancer compared with standard platinum-based chemotherapy, findings from a ... Read more
Testing for additional biomarkers along with the well-known biomarker CA125 can improve the detection of early-stage ovarian cancer, a new study shows. The blood-based assay could significantly improve patient ... Read more
Researchers from Clemson University and doctors from South Carolina’s Prisma Health-Upstate are collaborating to develop a screening tool that can identify ovarian cancer in its earlier stages, or even ... Read more
An analysis of circulating tumor DNA, or ctDNA, can help guide treatment decisions for patients with difficult-to-treat high-grade serous ovarian cancer, a study shows. The study, “Prospective Longitudinal ctDNA ... Read more
A new imaging-guided surgical technique that makes ovarian cancer tumors glow under near-infrared light can help surgeons remove tumors as small as 0.3 millimeters, a study in mice shows. ... Read more
A combination of Lynparza (olaparib) and the investigational PI3K inhibitor alpelisib is safe for the treatment of recurrent epithelial ovarian cancer and induces at least stable disease in more ... Read more